The Relationship Between Suicidal Behaviors and Zero Suicide Organizational Best Practices in Outpatient Mental Health Clinics

Abstract In order to provide effective mental health care to older adults with major neurocognitive disorders (e.g., Alzheimer’s disease and related dementias) within outpatient mental health clinics, mental health practitioners must possess a basic understanding of these disorders, the needs of and challenges faced by people living with dementia and their families, and effective treatment approaches for this population. The Mental Health Gero-Champions Program was established in 2015 at a large Veterans Affairs medical center with the aim of providing clinical support and opportunities for training to multidisciplinary mental health providers to enhance skills in assessing and treating older adults with neurocognitive disorders. This presentation will provide an overview of the Mental Health Gero-Champions Program, describe the development and implementation of this program, and discuss challenges and successes in sustaining this transformative initiative over time.

Download Full-text

Community treatment orders and antipsychotic long-acting injections

The British Journal of Psychiatry ◽

10.1192/bjp.195.52.s57 ◽

2009 ◽

Vol 195 (S52) ◽

pp. s57-s62 ◽

Cited By ~ 22

Author(s):

Tim J. Lambert ◽

Bruce S. Singh ◽

Maxine X. Patel

Keyword(s):

Mental Health ◽

Community Mental Health ◽

Legal Framework ◽

Community Treatment ◽

Mental Health Clinics ◽

Health Clinics ◽

Community Mental Health Clinics ◽

Long Acting ◽

The Relationship ◽

Treatment Order

BackgroundThe community treatment order (CTO) is the legal framework by which people in the community are compelled to accept treatment. Both antipsychotic long-acting injections (LAIs) and CTOs are used to address treatment non-adherence.AimsTo investigate the relationship between CTOs and LAI use in patients with schizophrenia.MethodPrescribing, demographic and CTO data were collected for patients from four community mental health clinics in Melbourne, Australia, in 1998 and 2002.ResultsAgainst a background of increasing use of oral second-generation antipsychotic (SGA) medication and decreasing use of LAIs, the rates of CTO implementation doubled from 13% to 26% of patients with schizophrenia between 1998 and 2002. Proportionally more patients with a CTO are prescribed LAIs rather than oral SGAs.ConclusionsThe relationship between receiving an LAI and being subject to a CTO is significant, and reflects the consideration given to enhancing adherence in a community mental health setting.

Download Full-text

Self-Esteem and Stigma Among Persons With Schizophrenia: Implications for Mental Health

Care Management Journals ◽

10.1891/cmaj.6.3.139 ◽

2005 ◽

Vol 6 (3) ◽

pp. 139-144 ◽

Cited By ~ 27

Author(s):

Melinda Berge ◽

Molly Ranney

Keyword(s):

Mental Health ◽

Selection Criteria ◽

Public Mental Health ◽

Self Esteem ◽

Management Model ◽

Perceived Stigma ◽

Mental Health Clinics ◽

Health Clinics ◽

Persons With Schizophrenia ◽

The Relationship

The purpose of the study was to examine the relationship between perceived stigma and self-esteem among adults with schizophrenia. The sample was drawn from three outpatient public mental health clinics in Southern California in September to November 2002. The following selection criteria were used to identify 31 respondents: (1) a diagnosis of schizophrenia and (2) stable symptoms. Self-esteem was measured using the Rosenberg Self-Esteem Scale. Stigma was measured using the Devaluation-Discrimination Measure. The strongest areas of stigma reported by those surveyed were related to hospitalization. The self-esteem of the respondents was moderately high. A Pearson’s r correlation indicated that there was a significant, moderately strong correlation, with a higher level of perceived stigma associated with a lower level of self-esteem. Findings suggest that using a strengths-based approach and a recovery case management model is recommended to decrease stigma and promote self-esteem among persons with schizophrenia.

Download Full-text

Rapid Conversion to Telemental Health Services in Response to COVID-19: Experiences of Two Outpatient Mental Health Clinics

Telemedicine Journal and e-Health ◽

10.1089/tmj.2020.0304 ◽

2020 ◽

Author(s):

Matthew C. Mishkind ◽

Jay H. Shore ◽

Kammy Bishop ◽

Kaitlin D'Amato ◽

Azure Brame ◽

...

Keyword(s):

Mental Health ◽

Health Services ◽

Telemental Health ◽

Mental Health Clinics ◽

Outpatient Mental Health ◽

Health Clinics ◽

Rapid Conversion

Download Full-text

Pharmacogenetic testing in outpatient mental health clinics

10.32469/10355/66723 ◽

2017 ◽

Author(s):

◽

Tammie Gainey

Keyword(s):

Mental Health ◽

Decision Making ◽

Clinical Decision Making ◽

Outpatient Clinics ◽

Future Research ◽

Mental Health Clinicians ◽

Pharmacogenetic Testing ◽

Mental Health Clinics ◽

Outpatient Mental Health ◽

Health Clinics

The purpose of this study was to evaluate mental health clinicians' perceived knowledge regarding pharmacogenetic testing; their attitude, receptivity towards, and confidence in pharmacogenetic testing; and how pharmacogenetic testing is being implemented to support decision making in outpatient clinics. This study was guided by Rogers' Diffusion of Innovation (DOI) Theory. An exhausted literature search was conducted to find studies on mental health clinicians' knowledge, perceived attitudes, and implementation of pharmacogenetic testing. The subject population included 28 mental health clinicians who are actively utilizing pharmacogenetic testing in outpatient mental health clinics. Participants responded to semi-structured open-ended prompts regarding knowledge, perceptions and implementation of pharmacogenetic testing in mental health outpatient clinics. Data were analyzed using a qualitative descriptive approach. Five relevant themes emerged related to the perceptions of pharmacogenetic testing, impact on clinical decision-making, associated concerns of pharmacogenetic testing, knowledge gaps among clinicians, and policy challenges. Overall, clinicians perceived pharmacogenetic testing beneficial to guide dosing and medication selection to decrease the risk of side effects and increase tolerability of psychotropic medications. This study will lead to future research to support shared decision-making around pharmacogenetics testing, medication adherence and tolerability, and setting guidelines for pharmacogenetics testing in mental health clinics.

Download Full-text